35.84 +0.32 (0.90%)
Pre-Market: 7:02AM EST
|Bid||35.80 x 300|
|Ask||35.82 x 2300|
|Day's Range||35.46 - 35.59|
|52 Week Range||34.52 - 44.54|
|PE Ratio (TTM)||28.06|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.01 (5.73%)|
|1y Target Est||42.72|
First targeted treatment approved for this rare eosinophil-driven disease, following FDA Priority Review LONDON , Dec. 12, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that ...
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GlaxoSmithKline Plc Here are 5 ETFs with the largest exposure to GSK-US. Comparing the performance and risk of GlaxoSmithKline Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
British pharmaceutical giant GlaxoSmithKline PLC said it finally has a full team in place at its vaccine hub in Rockville and is ready to take on some of the region's most well-known biotech competitors with part of its product lineup. This next year, officials said, will be about taking a leadership position in new vaccine technologies and advancing its priority projects, including a vaccine for shingles as well its vaccine candidate for respiratory syncytial virus, a common respiratory virus that often attacks infants and the elderly — and a key disease target already for major players such as MedImmune and Novavax Inc. "It's really getting down to business and doing the work," said Rip Ballou, vice president and head of GSK's (GSK) Global Vaccines U.S. Research and Development Center in Rockville.
Gilead has a potential GOAT on its hands, an analyst said Wednesday. Its drug, bictegravir, is likely to become the "Greatest Of All Time" among HIV drug launches.
Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.
Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...
GSK's Consumer Healthcare business reported revenues of ~2.0 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to ~1.9 billion pounds during 3Q16.
GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines * Deutsche Bank sends Trump financial details to Mueller ...
GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...
The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.
GlaxoSmithKline is using artificial intelligence to learn why certain HIV patients drop out of treatment. "The only clues that exist are in unstructured types of data," such as doctor's notes, ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of GlaxoSmithKline plc (LSE:GSK) as an investment opportunity. If you wantRead More...
GlaxoSmithKline’s (GSK) Vaccines segment reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
GlaxoSmithKline's (GSK) 3Q17 revenues of ~7.8 billion pounds represented 4.0% growth compared to its 3Q16 revenues of ~7.5 billion pounds.
In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
In 3Q17, United Therapeutics' (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.
Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.